Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers-Reference-Cited by-同舟云学术

Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers

Published:2021-12-15 Issue:24 Volume:131 Page:
ISSN:1558-8238
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Yarchoan Mark^ORCID,Cope Leslie,Ruggieri Amanda N.^ORCID,Anders Robert A.,Noonan Anne M.^ORCID,Goff Laura W.,Goyal Lipika,Lacy Jill,Li Daneng^ORCID,Patel Anuj K.^ORCID,He Aiwu R.^ORCID,Abou-Alfa Ghassan K.,Spencer Kristen,Kim Edward J.,Davis S. Lindsey,McRee Autumn J.,Kunk Paul R.^ORCID,Goyal Subir,Liu Yuan^ORCID,Dennison Lauren^ORCID,Xavier Stephanie,Mohan Aditya A.,Zhu Qingfeng^ORCID,Wang-Gillam Andrea^ORCID,Poklepovic Andrew^ORCID,Chen Helen X.^ORCID,Sharon Elad^ORCID,Lesinski Gregory B.^ORCID,Azad Nilofer S.

Funder

National Cancer Institute

National Institutes of Health

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/152670/files/pdf

Reference47 articles.

1. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States

2. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma